Sign in
Taking people in South KoreaPhase 3

Tests CKD-202A, a sacubitril and valsartan combination, for high blood pressure

Tests CKD-202A against valsartan in adults with essential hypertension, high blood pressure.

Key facts

Who runs it
Chong Kun Dang Pharmaceutical
Where
Wŏnju, South KoreaSee the site
Trial code
Registry title
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
Status
Recruiting
Phase
Phase 3
People taking part
324 people, planned
Started
14 Oct 2024
Expected to end
31 Dec 2026
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Sacubitril∙Valsartan(dose maintenance)
  • Sacubitril∙Valsartan(dose increasing)
  • Valsartan
Record updated
11 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with essential hypertension (high blood pressure with no other known cause) to test CKD-202A (Sacubitril∙Valsartan).

Age
19 years or older
Sex
All sexes can join.
Disease stage
Essential hypertension. The record gives no stage or severity.
Earlier treatment
Cannot have used other clinical trial drugs within 4 weeks before the screening visit.

Main reasons for not taking part

  • History of, or suspected, secondary hypertension
  • Orthostatic hypotension
  • Type 1 diabetes or poorly controlled diabetes
  • Drug or alcohol abuse within 24 weeks before screening
  • Pregnant or breastfeeding women

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Participants who are 19 years old or older
  • Participants who have voluntarily decided to participate in this clinical trial and signed ICF

Who cannot take part

  • Participants who require combination administration of antihypertensive drugs other than clinical trial drugs during the clinical trial participation period
  • Participants who treated other clinical trial drugs within 4 weeks of screening visit
  • Pregnant women, lactating women, or Subjects who do not agree to use appropriate contraception during the clinical trial period and for two weeks after the end of administration of the last clinical trial drug
  • Participants with a history of secondary hypertension or suspected secondary hypertension
  • Participants with type 1 diabetes or poorly controlled diabetes
  • Participants with a history of drug or alcohol abuse or suspected patient within 24 weeks as of the time of screening
  • Participants with a orthostatic hypotension
  • Participants who are unable to participate in this clinical trial at the discretion of the investigator

Where in South Korea

  • Wonju Severance Christian HospitalWŏnju, South KoreaContact: Byungsu Yoo, PITaking people

About the trial

What the trial wants to find out

Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A(Sacubitril∙Valsartan)

The 3 groups in the trial

  • Test Group1Treatment being tested

    Treatment: Sacubitril∙Valsartan(dose maintenance)

  • Test Group2Treatment being tested

    Treatment: Sacubitril∙Valsartan(dose increasing)

  • CONTROLExisting treatment, for comparison

    Treatment: Valsartan

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-blind, Active-controlled, Multi-center, Therapeutic Confirmatory, Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
Plain-language title
Tests CKD-202A, a sacubitril and valsartan combination, for high blood pressureGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
11 December 2025